Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Abstract In 2022, the European Atherosclerosis Society (EAS) published a new consensus
statement on lipoprotein (a)[Lp (a)], summarizing current knowledge about its causal …

Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …

Background and aims Lipoprotein (a) is a well-known causal risk factor for cardiovascular
morbidity and mortality. Little is known about the effect of age and sex on lipoprotein (a) …

Abstract Background Lipoprotein (a)[Lp (a)] is one of the residual risk factors for
cardiovascular disease (CVD) in the setting of optimal low-density lipoprotein cholesterol …

Familial hypercholesterolemia (FH) is the most frequent genetic disorder resulting in
increased low-density lipoprotein cholesterol (LDL-C) levels from childhood, leading to …

Background Elevated lipoprotein (a)[Lp (a)] level is an independent genetic risk factor that
increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 2–4 fold. We aimed …

Lipoprotein (a) or lipoprotein “little a”[Lp (a)] is an under-recognized causal risk factor for
cardiovascular (CV) disease (CVD), including coronary atherosclerosis, aortic valvular …